306
Views
87
CrossRef citations to date
0
Altmetric
Review

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

, &
Pages 231-238 | Published online: 09 Jan 2014

References

  • Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminum compounds used as adjuvants in vaccines. Pharm. Res. 7(12), 1282–1288 (1990).
  • Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15(2), 176–178 (1997).
  • Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur j Epidemiol 15(6), 573–576 (1999).
  • Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol 6, 495–524 (1995).
  • •A review of the immunostimulating properties of monophosphoryl lipid A and related compounds.
  • Brandenburg K, Lindner B, Schromm A et al Physicochemical characteristics of triacyl lipid A partial structure 0M-174 in relation to biological activity. Eur Biochem. 267(11), 3370–3377 (2000).
  • Pizza M, Giuliani MM, Fontana MR et al Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17-19), 2534–2541 (2001).
  • Kensil CR. Saponins as vaccine adjuvants. Grit. Rev. Ther. Drug Carrier Syst. 13(1–2), 1–55 (1996).
  • •A review of the immunostimulating properties of saponins, including QS21.
  • Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11(9), 909–913 (1993).
  • Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol. Cell. Biol. 74(1), 8–25 (1996).
  • Trinchieri G. Interleukin-12 and its role in the generation of Thl cells. ImmunaToday14(7), 335–338 (1993).
  • McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 19(17-19), 2657–2660 (2001).
  • Cox JC, Coulter AR. Adjuvants — a classification and review of their modes of action. Vaccine 15 (3), 248–256 (1997).
  • Kenney RT, Regina RN, Pichyangkul S, Price VL, Engers HD. Second meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization, Mondiale de la Sante Fondation Merieux, Annecy, France, 5–7 June 2000. Vaccine 20(17–18), 2155–2163 (2002).
  • Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 68(3), 258–259 (1974).
  • Sadoff JC, Ballou WR, Baron LS et al Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240(4850), 336–338 (1988).
  • Sedegah M, Sim BK, Mason C et al Naturally acquired CDS+ cytotoxic T-lymphocytes against the Plasmodium falciparum circumsporozoite protein. Immunol 149(3), 966–971 (1992).
  • Tsuji M, Zavala E T-cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 19(2), 88–93 (2003).
  • •A thoughtful review and discussion of the potential role of cell-mediated immune responses in protection against the preerythrocytic stage of blaparlim.
  • Newman MJ, Wu JY, Gardner BH etal. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15(9), 1001–1007 (1997).
  • Kumar S, Miller LH, Quakyi IA etal. Cytotoxic T-cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 334 (6179), 258–260 (1988).
  • Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl. Med. 336(2), 86–91 (1997).
  • ••The first demonstration in human volunteers of the efficacy of RTS,S/AS02 vaccination against homologous P falciparum sporozoite challenge in a laboratory setting.
  • Doherty JE Pinder Tornieporth, M. N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Ainj Trop. Med. Hyg. 61(6), 865–868 (1999).
  • Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. I Infect. Dis. 183 (4), 640–647 (2001).
  • Stoute JA, Kester KE, Krzych U et al Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.j Infect. Dis. 178(4), 1139–1144 (1998).
  • Bojang IKA, Milligan PJ, Pinder M et al Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falcipamm infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (9297), 1927-1934 (2001).
  • ••The first demonstration in human volunteers of the efficacy of the RTS,S/AS02 vaccine against natural challenge by P falciparum-infected mosquitoes in a field setting.
  • Lalvani A, Moris P, Voss G et al. Potent induction of focused Thl-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falcipamm malaria vaccine. I Infect. Dis. 180(5), 1656–1664 (1999).
  • •A preliminary analysis of the nature of the cell mediated immune responses induced by RTS,S/AS02 in human volunteers.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.